Viewing Study NCT03693092


Ignite Creation Date: 2025-12-24 @ 3:28 PM
Ignite Modification Date: 2026-02-20 @ 6:24 PM
Study NCT ID: NCT03693092
Status: UNKNOWN
Last Update Posted: 2018-10-02
First Post: 2018-09-30
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: LAmbre™ Left Atrial Appendage Closure System Follow-Up Study
Sponsor: Lifetech Scientific (Shenzhen) Co., Ltd.
Organization:

Study Overview

Official Title: LAmbre™ Left Atrial Appendage Closure System Post-Market 2-5 Years Follow-Up Study
Status: UNKNOWN
Status Verified Date: 2018-09
Last Known Status: NOT_YET_RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The purpose of this study is to conduct a continuous telephone follow-up study on subjects who had completed the one-year follow-up of the LAmbre™ left atrial appendage (LAA) system registration trial. The follow-up time was 2 years, 3 years, 4 years and 5 years after left atrial appendage closure operation, to evaluate the long-term safety and effectiveness of LAmbre™ LAA Closure System.
Detailed Description: All subjects who completed 1-year follow-up of the LAmbreTM LAA system registration trial will be conducted 2 years, 3 years, 4 years and 5 years follow-up by the telephone call.

During the follow-up, the investigator or his/her designee will use a standardized form to record the occurrence of the subject's safety events and validity endpoint by telephone,and complete the safety and efficacy summary report. The endpoints of the study included compound events, MACCE events, stroke, haemorrhage and other events.

Study Oversight

Has Oversight DMC: True
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: